EP Patent

EP4669321A1 — METHOD FOR THE USE OF FACTOR B INHIBITORS

Assigned to Novartis AG · Expires 2025-12-31 · 0y expired

What this patent protects

Described herein are methods of treating immune complex mediated membranoproliferative glomerulonephritis (IC-MPGN) with the Factor B inhibitor iptacopan or a pharmaceutically acceptable salt thereof, e.g. iptacopan hydrochloride.

USPTO Abstract

Described herein are methods of treating immune complex mediated membranoproliferative glomerulonephritis (IC-MPGN) with the Factor B inhibitor iptacopan or a pharmaceutically acceptable salt thereof, e.g. iptacopan hydrochloride.

Drugs covered by this patent

Patent Metadata

Patent number
EP4669321A1
Jurisdiction
EP
Classification
—
Expires
2025-12-31
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.